Year: 2024

DALLAS, Oct. 31, 2024 (GLOBE NEWSWIRE) — Applied Digital Corporation (Nasdaq: APLD) (“Applied Digital” or the “Company”), a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (HPC) applications, today announced the upsize and pricing of its offering of $375 million aggregate principal amount of 2.75% Convertible Senior Notes due 2030 (the “Convertible Notes”). The Convertible Notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Key Elements of the Transaction:$375 million 2.75% Convertible Notes offering (32.5% conversion premium) Capped call transactions entered into in connection with the pricing of Convertible Notes...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 Third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023 Third quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD Third quarter 2024 Libtayo® global net sales increased 24% to $289 million versus third quarter 2023 Third quarter 2024 GAAP diluted EPS increased 30% to $11.54 and non-GAAP diluted EPS(a) increased 8% to $12.46 versus third quarter 2023; third quarter 2024 includes unfavorable $0.43 impact from acquired IPR&D charge FDA approved Dupixent as first-ever biologic therapy in U.S. for treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic...

– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the...

WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 29, 2024. Third quarter financial summaryGAAP revenue of $764.4 million, up 2.4% compared to the prior year period, up 2.2% on a constant currency basisGAAP diluted EPS from continuing operations of $2.36, compared to $2.91 in the prior year periodAdjusted diluted EPS from continuing operations of $3.49, compared to $3.64 in the prior year period2024 guidance summaryLowering GAAP revenue growth guidance range to 2.90% to 3.40%Lowering adjusted constant currency revenue growth guidance range to 3.50% to 4.00%Raising GAAP EPS from continuing operations guidance range to $6.65 to $6.95Raising the low end of adjusted diluted EPS from continuing operations...

BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash. The departing senior executives include Chief Medical Officer Dr. James Ferguson, Chief Business Officer Thomas Hoover and Chief Technology Officer Dr. Hui Liu. The Board intends to retain an advisor to assist the Company with the potential asset sale of MAT2203, its lead Phase...

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail:Date: Thursday, November 7, 2024Time: 8:30 a.m. Eastern TimeLink: https://edge.media-server.com/mmc/p/e6my278s   To access the conference call, please register using https://edge.media-server.com/mmc/p/e6my278s. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log...

SINGAPORE, Oct. 31, 2024 (GLOBE NEWSWIRE) — Sound Group Inc. (“Sound Group” or the “Company”) (NASDAQ: SOGP), formerly known as LIZHI INC., a global audio-centric social and entertainment company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the “SEC”) on October 31, 2024 (U.S. Time). The annual report, which contains the Company’s audited consolidated statements, can be accessed on the SEC’s website at http://www.sec.gov and the Company’s investor relations website at https://ir.soundgroupinc.com/. The Company will provide a hard copy of its annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to ir@soundgroupinc.com or the Investor Relations Department at Sound Group...

Revenue1 increased 6% to $2.3 billion for the quarter with organic growth of 6% for the quarter Diluted Loss2 per Share was $16.44 for the quarter Adjusted Diluted Earnings per Share were $2.93 for the quarter, up 31% from prior year Operating Margin2 was (33.5)% for the quarter Adjusted Operating Margin was 18.1% for the quarter, up 190 basis points from prior yearLONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW) (the “Company”), a leading global advisory, broking and solutions company, today announced financial results for the third quarter ended September 30, 2024. “We had another strong quarter fueled by revenue growth, operating leverage and the success of our Transformation program. Our revenue growth of 6% for the quarter is evidence that our value proposition is continuing to resonate in the market and that...

Company to Host Conference Call and Webcast at 8:30 AM ET Today PALM BEACH GARDENS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (“we,” “our,” the “Company” or “GECC”) (NASDAQ: GECC), a business development company, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter and Other Recent Highlights:Net investment income (“NII”) for the quarter ended September 30, 2024 was $4.1 million, or $0.39 per share, as compared to $3.1 million, or $0.32 per share, for the quarter ended June 30, 2024. Net assets were $125.8 million, or $12.04 per share, on September 30, 2024, as compared to $126.0 million, or $12.06 per share, on June 30, 2024. In September 2024, issued $36.0 million of 8.125% unsecured notes due 2029 (the “GECCH Notes”) and an additional $5.4 million in October...

Seoul, South Korea, Oct. 31, 2024 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, announced that Gravity’s wholly-owned subsidiary, Gravity Game Vision Co., Ltd, officially launched the 3D MMORPG mobile game, Ragnarok: Rebirth (Chinese Title: 中仙境傳說：重生), on October 31, 2024 at 9:00 am (HKT) in Taiwan, Hong Kong and Macau. Ragnarok: Rebirth is idle content, which reduces fatigue and provides rich rewards that allow users to grow their characters quickly over time. The game provides both vertical and horizontal screens for user convenience. In June of this year, immediately after its launch in Southeast Asia, Ragnarok Rebirth ranked the first in free popular game in the Apple App Store in Thailand, the Philippines, Indonesia, and Malaysia, proving...